Allurion Technologies Inc (ALUR) Quote

ALUR...................................a/h

ALUR...............................................................p/m

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
Four abstracts presented at the European Congress on Obesity
Data indicate potential synergies of Allurion’s swallowable ProcedurelessTM intragastric balloon (the “Allurion Balloon”) and Virtual Care Suite (VCS) (together, the “Allurion Program”) with normal dosing of GLP-1s, building upon previous data on the combination of the Allurion Program with low-dose GLP-1s
GLP-1s used in combination with the VCS lead to an average of 6.1% increase in lean body mass, indicating that maintaining muscle may be possible even at normal doses for GLP-1s with Allurion’s AI-powered behavioral support
Allurion Balloon in combination with GLP-1s leads to an average of 21.2% reduction in body weight, potentially representing an option for patients with severe obesity seeking an alternative to bariatric surgery
2,000 patients using the Allurion Program without GLP-1s showed an average of 12.4% reduction in body weight with a 9.8% increase in muscle mass, underscoring the safety and effectiveness of the Allurion Balloon as a standalone therapy
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass preservation.

In one study of 138 patients prescribed GLP-1s with normal dose escalation who used the VCS, patients increased lean body mass by an average of 6.1%, increased muscle mass by an average of 6.4%, and decreased fat mass by an average of 10.2% after four months of using the VCS, indicating that Allurion’s AI-driven behavioral support may help patients maintain muscle, even at normal or high doses of GLP-1 therapy.

In another study of 60 patients who were treated with the Allurion Balloon and then semaglutide, patients achieved an average of 21.2% reduction in total body weight and improvements in metabolic parameters over a 10-month period. This combination therapy approach led to outcomes similar to those achieved with bariatric surgery.1

“The combination of the Allurion Program and semaglutide represents a significant advancement in weight loss,” said Dr. Roberta Ienca, physician at Nuova Villa Claudia Clinic, Rome, Italy, who oversaw this study. “While using low doses of semaglutide in combination with the Allurion Program may be preferable in most patients, there is a role for using normal dosing and escalation schedules as well, especially in patients with severe obesity seeking an alternative to bariatric surgery. This innovative approach may also address the challenges of weight regain often seen with the use of GLP-1 medications alone, potentially providing a more sustainable path to achieving and maintaining a healthier weight.”

Two other studies pertaining to the Allurion Program were also presented at ECO.

In one study, 43 patients prescribed GLP-1s who used the VCS achieved an average of 17.3% reduction in total body weight at nine months. Improved weight loss outcomes were observed in this study compared to the weight loss observed in US studies where the VCS was not used. Such other studies reported an average of 15.2% total body weight loss for patients prescribed tirzepatide and an average of 7.9% total body weight loss for patients prescribed semaglutide, each at 12 months2. These outcomes suggest that AI-driven interventions can play a crucial role in augmenting traditional treatment methods.

In another study, which was a large single-center experience of 2000 patients treated between 2017 and 2024 with the Allurion Program, patients achieved an average weight reduction of 12.4% after four months with an average of 9.8% increase in muscle mass after six months. These results demonstrate a potentially safe, effective, and scalable program for obesity clinics.

Details of the Presentations are as follows:

Title: Optimizing Body Composition and Lean Mass Preservation: The Value of AI-Powered Digital Platforms and Health Coaches for Patients on GLP-1 Medications

Presenter: Bill Nadeau, RD, Vice President, Medical Affairs, Allurion

Title: The New Era of Combination Weight Loss Treatments: The Swallowable Gastric Balloon Program and the Anti-Obesity Medication Semaglutide

Title: Enhancing Weight Loss Outcomes with GLP-1 Medications: The Role of AI-Powered Digital Platforms and Health Coaches

Presenter: Bill Nadeau, RD, Vice President, Medical Affairs, Allurion

Presenter: Roberta Ienca, MD, Weight Management Center, Nuova Villa Claudia Clinic, Rome, Italy

Title: Exceptional Outcomes and Safety Profile in the First 2,000 Patients Treated with the Allurion Balloon Program at a Single Spanish Bariatric Center

Presenter: Adelardo Caballero, MD, Instituto de Obesidad, Madrid, Spain

About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “target,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the expected benefit of a combination approach of the Allurion Program and GLP-1 use for weight loss management, market acceptance of such new combined therapies, the uniqueness of Allurion’s product and service offerings and other statements about future events that reflect the current beliefs and assumptions of Allurion’s manage

alur...............................................https://stockcharts.com/h-sc/ui?s=ALUR&p=W&b=5&g=0&id=p86431144783

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 medication through 8 months.

“I believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages,” said Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch who oversaw this case series. “These results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects—including muscle wasting—and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.”

Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost1 and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit2, due in part to side effects, dose escalation required for continued weight loss, and cost. Semaglutide dosing is typically increased to 2.4mg, over two times higher than the maximum dose of 1.0mg used in the combination approach.

“Muscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests that a combination approach that leverages Allurion’s full program—which includes the balloon, our Virtual Care Suite, and our behavior change program—may be a compelling solution,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.”

Additional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.

Just a FYI - The ALUR program includes weight training and protein intake, today's news doesn't even include random subjects..

ALUR.................................https://stockcharts.com/h-sc/ui?s=ALUR&p=W&b=5&g=0&id=p86431144783

ALUR: And yet ANOTHER PR from this wanna-be FAT CAT Firm!! (No pun intended.)
https://finance.yahoo.com/m/abc88d2f-1b90-3ebd-bb20-4be6121c7545/allurion-catapults-200-on.html

ALUR: "Institutional Investors" get some ---
https://finance.yahoo.com/news/allurion-raise-approximately-7-4-143000224.html
(But STILL a small FLOAT.)

In truth, Mr. Zardiw is a LADY. (HA-HA-HA!!)

LOOKS LIKE ZARDIW TRYING TO SELL HIS SCANNING TECHNOLOGY

ALUR.WS: So, Colonel TT-16, ya think YOUR Wall Street SCANNERS are really KOOL?? (Check out MY disruptive new one, below, Homeboy!! I'm the Dude, sportin' the turban!!)

WTF....WHAT HAPPEBED TO OLE SCHOOL DUMBELS AND BARBELLS

ALUR.WS: At only $0.09, this Firm's WARRANTS have a very 'ALUR-ing' price, Folks. (No pun intended.)

its crazy right
$ALUR who else is following me? https://t.co/QOsJ1GfjM3 pic.twitter.com/jR9r2smVnQ— THE FINAL COUNTDOWN (@THIS_TIME_X) January 24, 2025

Message in reply to:
$7.51 still a little left for latecomers just cash it out now

$17.27 + 370%

$16.68 + 339%

Geeze! I am not in this monster😭

Its at 11$

$7.51 still a little left for latecomers just cash it out now 

Most are scams however I hope you made $$$ here. I am not in this.

ride or die balloon scam
shouldve said the balloon uses AI technology to see whether GLP1 is needed

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.2 In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.

“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care.”

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Forward-Looking Statements

BARCHART medical device sector of 112 stocks
ALUR is near the https://www.barchart.com/stocks/quotes/ALUR/competitors?quoteSectors=-384B&viewName=main&orderBy=weightedAlpha&orderDir=desc&page=3

ALUR, one year graph

Omar Ishrak on the board, former CEO of MDT
CEO is a smart but a biogrifter I believe
they will issue a new PR soon about the gastric balloon... on the low float

really . and this trades SMH

flim flam

ALUR: Looks like its PRICE is on a successful 'DIET' right now --- figuratively speaking, that is.

Losing weight here

ALUR: Glad ya got a CHUCKLE behind my post there, Bro!! (Heck, and regarding incorrigibly FAT Americans --- of all Races, Creeds, Ethnicities, National Origins, & Socio-Political persuasions --- see ME below, just yesterday, simutaneously celebrating the glorious "JUNETEENTH" holiday, and otherwise performing my daily HIP-HOP-CARDIO-FAT-BURNER-WORKOUT routine over here in balmy San Diego, CA!! LIFE IS GOOD --- ain't it, Brutha!!!???)

ALUR: A big JOKE, Bro!! (Did you not see the PARENTHETICAL, within which I clearly posted, "Just kidding!!"???)

ALUR...............................https://stockcharts.com/h-sc/ui?s=ALUR&p=W&b=5&g=0&id=p86431144783

LMAO investing in America!!! Haha!!
Took position here in $ALUR! ALUR

GREAT NEWS:
America is VERY OBESE!
7/10 kids OBESE
8/10 adults OBESE

No wonder BIG PHARMA loves Americans!!

Their OBESE, and get diabetes, hypertension, strokes, heart attacks etc.

Americans have lots of FAT and it shows!
BOTTOMLINE, here we have a company with amazing results and can lead to BIG BUCKS!

In for nice position here as this can and will go way north here in my opinion!

Trendtrade is right, gym, diet etc .. but based on the MASSIVE OBESITY problem Americans have , this company can make HUNDREDS of millions with their product!

Yo to each and their own, and no theirs no fat shaming in this post.
Just honest assessment with today’s news we have a MASSIVE MOVE inbound due to America’s obesity problem!
All my opinion!
Maverick
$ALUR

This a not not joke? Not!

ALUR: Hey, when NOT workin' stocks, I spend nearly all day seeing what the phrase BIG FAT NAKED WOMEN will generate up on Porn-Hub, You-Porn, & X-Hamster sites!!! (Just kidding!!) And I'll leave you with THAT disgusting thought, Bro!! Happy trading!!

Weight-loss is now a miracle. About to make sandwiches dissappear big gulp style

ALUR: A wild, wild, PRICE movement day for this --- shall we say --- rather 'MURACULOUS' stockl!!

So Murican!

ALUR: Hey, Bro, and a hearthy THANKS for that addition to my Personal Lexicon!!! (Heck, I feel like screaming 'MURICA' --- similar to yelling 'EUREKA', if one were to dig-up a 200-lb. Gold nugget along the "American River" over here in balmy Calif.!!)

Who says you can't learn anything on ihub?

ALUR: What??? I had to look-that-one-up, Dude!! "Murica"??? (Never heard that word, & what a phantasmagorical DEFINITION!!!)
https://www.dictionary.com/e/slang/murica/
////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Anything that cures fat that requires no exercise sells
Murica

ALUR: Indeed!! (Hey, Dude, when I first did a cursory reading of their PR today --- NO joking here --- I believed that they had INCREASED the beneficial MUSCLE body mass of patients/subjects who were simply too SKINNY, or otherwise UNDERWEIGHT for persons of their age. I.e., folks of all ages who looked like, 'REFUGEES-FROM-AUSCHWITZ' death camp, circa 1945!!!)

Sounds like body shaming. Horrible comment when big is beautiful

ALUR: Of course!!! (Heck, these days, the peeps exiting any Starbucks look more like folks leaving a "DAIRY QUEEN" or "BASKIN ROBBINS" holding a half-gallon-size, "Bananna-Moca-Choco-Latte-Icecream-Coffee-Supreme"!!!)

ALUR: Hey, Bro, do that!! (Via iHub PM, if you like; and DON'T worry, if I just LOVE your glorious physique, I will NOT ask to MARRY you nor have your CHILD!!! NOT that there's anything WRONG with that --- thanks, Jerry Seinfeld!! I.e., I am NOT a 'FRUITER' --- although I play one on that 'Shit's-Creek' sitcom.)

Can I add shakes biggy size?

Maybe I should send pic of what pumping weights and eating mainly meat at 61 looks like and no juice!

ALUR: Heck, Bro, "Burgers-&-Fries" should be the ONLY food Americans are PERMITTED to eat!!! As recommended by the US Sturgeon General, & Department of Health & Human Disservices!!!